基于化基 propyl β-cyclodextrin/四度性基的双功能纳米颗粒用于性结肠炎干预
Shanglin Li1, Shuaiyan Liu1, Yiding Yu2
1Jilin Provincial Key Laboratory of Nutrition and Functional Food, College of Food Science and Engineering, Jilin University, Changchun 130062, PR China.
Food research international (Ottawa, Ont.)
|February 28, 2026
概括
新的口服纳米颗粒结合了抗炎性黄素与微生物组调节的素,用于性结肠炎 (UC) 治疗. 这些可适应的纳米颗粒显示出治疗结肠炎和推进精密营养的前景.
科学领域:
- 生物材料科学 生物材料科学
- 胃肠病学 胃肠病学
- 微生物组研究 微生物组研究
背景情况:
- 性结肠炎 (UC) 治疗由于胃肠道环境的复杂性而面临挑战.
- 口服纳米粒子 (NP) 需要适应性,以便在肠道中进行一致和特定的干预.
研究的目的:
- 为综合性UC治疗设计和开发适应胃肠微环境的NP.
- 为了利用黄素 (Cur) 的抗炎作用和黄素 (Cy) 的微生物组调节.
- 通过自组装,双功能NP实现双重治疗结果.
主要方法:
- 通过化合成CA修饰的HPCD (CACD) 和SA修饰的HPCD (SACD).
- 自组装的NP使用HTCC,Cur和Cy与修改的HPCD.
- 在pH范围 (2.0-7.0) 中评估了NP封装效率 (EE) 和容量 (EC).
- 在体内评估治疗疗效,分析细胞因子水平,组织损伤和肠道微生物组合.
主要成果:
- 在pH值2.0-7.0之间,NP表现出高CurEE和EC,这表明胃肠道具有显著的适应性.
- 在体内研究表明,结肠炎症状有所改善,促炎性细胞因子减少,组织损伤减轻.
- 特定的NP配方调节了肠道微生物群,丰富了有益的细菌 (Eubacterium siraeum_group, Prevotellaceae) 或有利于Peptococcus,可能增强免疫调节.
结论:
- 双功能NP为性结肠炎提供了一种新的治疗策略.
- 这些NP代表了精准营养干预措施的有希望的方法.
- 开发的NP证明了集成UC治疗的有效抗炎和微生物组调节能力.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
577
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
577
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
577
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
577
Drugs for Treatment of Diarrhea-Predominant IBS
799
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
799
Peptic Ulcer Disease IV: Management
580
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
580
Drugs for Treatment of Constipation-Predominant IBS
1.0K
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
1.0K
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.8K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.8K


